Arkin Bio Ventures is the biotech venture capital arm of Arkin Capital, based in Herzliya, Israel. It identifies, invests in, and accompanies innovative early- and mid-stage companies with breakthroughs in areas such as immunotherapy, oncology, metabolism, microbiome, CNS, autoimmune and orphan diseases, and drug delivery platforms.
33% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (53% of deals). Average disclosed round size is $78.7M (across 32 rounds with reported amounts).
Portfolio
25
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
2
Team
AL
ALON LAZARUS – in Memoriam
Managing Partner
NS
NADAV SHIMONI
Managing Partner
IA
ITAI ARKIN
Director, Global Capital Markets
RU
RIVKA ULIEL
Tax Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
36 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrossbow | Series B | — | Mar 2026 |
 Ambros Therapeutics | Series A | $125M | Dec 2025 |
 Newleos | Series A | $93.5M | Feb 2025 |
| NNewleos Therapeutics | Series A | $93.5M | Feb 2025 |
| Newleos | Series A | $93M | Jan 2025 |
| NNewleos Therapeutics | Series A | $93.5M | Jan 2025 |
| Ambros Therapeutics | Series A | $125M | Jan 2025 |
 Reunion Neuroscience | Series A | $103M | May 2024 |
| BBluejay Therapeutics | Series C | $182M | May 2024 |
| HHI-Bio | Series B | $95M | Jan 2024 |
 Entact Bio | Series A | $81M | Dec 2022 |
 Entact | Series A | $81M | Dec 2022 |
 Photys | Series A | $75M | Sep 2022 |
| BBluejay Therapeutics | Series B | $41M | Aug 2022 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Photys Therapeutics | Series A | $75M | Jan 2022 |
| Entact Bio | Series A | $81M | Jan 2022 |
| WWerewolf Therapeutics | Series A | $120M | Apr 2021 |
| WWerewolf Therapeutics | Series B | $72M | Jan 2021 |
| RRedPin Therapeutics | Series A | $15.5M | Mar 2020 |
 Keros Therapeutics | Series C | $56M | Mar 2020 |
 BioSight | Series C | $19M | Jan 2020 |
| PPi Therapeutics | Series B | $19.7M | May 2019 |
 Metabomed | Unknown | $12.5M | Jan 2019 |
 Werewolf | Series A | $56M | Jan 2019 |
Page 1 of 2
Top Co-Investors
Longwood Fund11 shared
MPM Capital9 shared
RA Capital Management8 shared
Novo Holdings A/S6 shared
4BIO Capital6 shared
Pontifax5 shared
UPMC Enterprises5 shared
Qiming Venture Partners USA4 shared
Eli Lilly and Company4 shared
Mass General Brigham Ventures4 shared
Abingworth LLP4 shared
Sixty Degree Capital4 shared
Adage Capital Management4 shared
Goldman Sachs Alternatives4 shared
DCVC3 shared
Apollo Health Ventures3 shared
Foresite Capital3 shared
venBio3 shared
Logos Capital3 shared
Surveyor Capital3 shared
Last updated: 20 October 2026